)
Visual
test
Galecto
Galecto (GLTO) investor relations material
Galecto Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Mar, 2026
Executive summary
Completed acquisition of a pipeline targeting mutant calreticulin-driven MPNs, including lead candidate DMR-001, and secured $285 million in private financing.
Strengthened leadership with new COO and CMO appointments, enhancing hematology/oncology expertise.
Changed company name and began trading under new ticker symbol on Nasdaq in March 2026.
Financial highlights
Cash and cash equivalents were $257.6 million as of December 31, 2025, rising to $535 million by February 28, 2026, after a public offering.
Research and development expenses increased to $26.9 million in 2025 from $6.4 million in 2024, driven by acquisition and expanded activities.
General and administrative expenses decreased to $9.7 million in 2025 from $10.5 million in 2024, mainly due to lower stock-based compensation.
Net loss for 2025 was $209.8 million, up from $21.4 million in 2024, primarily due to $174.3 million in acquired in-process R&D costs.
Outlook and guidance
IND or CTA submission for DMR-001 expected mid-2026; DMR-002 in the second half of 2026; DMR-003 in 2027.
Two clinical proof-of-concept datasets for DMR-001 anticipated beginning mid-2027.
Cash position expected to fund operations into Phase 3 development of DMR-001.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Galecto
- Damora advances potent CALR-targeted therapies for ET and MF, aiming for broad clinical impact.GLTO
Leerink Global Healthcare Conference 20269 Mar 2026 - Key proposals include stock conversion, capital increase, redomestication, and new equity plans.GLTOProxy Filing31 Dec 2025
- BRM-1420, a dual ENL-YEATS/FLT3 inhibitor, advances toward clinical trials for high-risk AML.GLTOOppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 202524 Dec 2025
- Shareholders will vote on key proposals to support growth, redomestication, and new equity plans.GLTOProxy Filing16 Dec 2025
- Advancing preclinical antibody and small molecule therapies for blood cancers after major PIPE raise.GLTORegistration Filing16 Dec 2025
- Annual meeting to vote on director elections, stock issuance, and auditor ratification.GLTOProxy Filing2 Dec 2025
- Annual meeting to vote on directors, stock conversion, auditor, and review governance and compensation.GLTOProxy Filing2 Dec 2025
- Key votes include director elections, stock issuance approval, and auditor ratification.GLTOProxy Filing2 Dec 2025
- Acquisition expands blood cancer pipeline and secures $285M funding for clinical milestones through 2029.GLTOM&A Announcement17 Nov 2025
Next Galecto earnings date
Q1 202630 Apr, 2026
Galecto
Next Galecto earnings date
Q1 202630 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage